| For Practicing Rheumatologists |
See all
|
Article Summary
|
|
|
Manadan AM et al. - New therapeutic agents directed at antagonizing two previously untargeted pathways have recently been approved by the U.S. Food and Drug Administration for RA patients who have had inadequate responses to anti-TNF therapy or who have failed to maintain an adequate clinical response. We review the data supporting the use of these agents, rituximab and abatacept.
|
 |
 |
| Read a Different Specialty |
 |
|
|
|
 |
| Profession Index |
 |
|
|
|
 |
|
|